Webinars

Learn valuable perspectives by watching presentations from industry panelists.

Improving Signal Detection in Rare Disease Clinical Trials

Improving Signal Detection in Rare Disease Clinical Trials

High-quality data are critical when seeking to measure treatment outcomes, but this is especially challenging in rare disease trials where the stakes are high with complex assessments and a limited number of eligible participants. In this webinar, Dr. Pam Ventola will describe customized rater training approaches that meet sponsors’ needs but also are flexible and efficient so to be feasible for sites.

September 21, 2020
A Better Way to Measure Cognitive Safety & Tolerability

A Better Way to Measure Cognitive Safety & Tolerability

Learn how to leverage integrated digital cognitive assessments and patient reports for advanced insights, streamlined delivery and lower burden. Watch the webinar from ERT and Cogstate to learn the value of assessing cognitive safety and tolerability throughout the drug development process, key considerations for selecting and optimizing computerized cognitive assessments, and more.

July 30, 2020
Remote Administration Considerations for Conventional and Computerized Clinical Outcome Assessments

Remote Administration Considerations for Conventional and Computerized Clinical Outcome Assessments

As the COVID-19 pandemic spread, research teams worldwide quickly adapted study plans to safely continue research whenever possible. While some observational studies were put on hold entirely, other therapeutic trials were continued with many or all study activities occurring remotely.

June 23, 2020
Clinical Outcome Assessments in Preclinical Alzheimer’s Disease: Considerations for Global Clinical Trials

Clinical Outcome Assessments in Preclinical Alzheimer’s Disease: Considerations for Global Clinical Trials

Clinical trials designed to study interventions at the preclinical AD stage are using fit-for-purpose clinical outcome assessments that have high validity and reliability for the detection of cognitive change at this early stage of the illness. This webinar outlines the application of several preclinical stage instruments for use in industry clinical trials.

November 28, 2019
Selecting Cognitive & Behavioral Endpoint Measures for Trials in Rare Epilepsy and MPS Disorders

Selecting Cognitive & Behavioral Endpoint Measures for Trials in Rare Epilepsy and MPS Disorders

Clinical trials in patients with rare disease present considerable challenges, as patients with these conditions are typically heterogeneous and many are quite impaired. In this webinar, Dr. Pamela Ventola describes important factors to consider when selecting cognitive and behavioral endpoints for these trials and shares strengths and application considerations for several key scales.

November 28, 2019
Using Cognition to Guide Decisions on the Safety and Tolerability of Drugs in Clinical Development

Using Cognition to Guide Decisions on the Safety and Tolerability of Drugs in Clinical Development

In clinical trials, changes in performance on cognitive tests can provide a sensitive index of the impact of a drug on the central nervous system. This webinar details how the detection of decline in specific aspects of cognition, or in cognition in general, is important for making decisions about target engagement, maximum tolerated dose and pharmacodynamic profile.

July 25, 2019
Measuring Cognitive Effects of Pediatric Oncology Treatments Using Computerized Assessments

Measuring Cognitive Effects of Pediatric Oncology Treatments Using Computerized Assessments

In recent years the neurocognitive effects of treatments for pediatric cancers have been acknowledged in the scientific literature. However, in many cases the magnitude of these deficits and the long-term impact on cognitive maturation remain unclear. In this webinar Dr. Adrian Schembri and Dr. Kristina Hardy share their collective experience on the application of computerized cognitive assessments in pediatric oncology.

May 15, 2019
Evaluating Cognition in Parkinson’s Disease Clinical Trials

Evaluating Cognition in Parkinson’s Disease Clinical Trials

The past two decades have seen multiple industry trials explore the impact of drug treatments on cognition in Parkinson’s disease and PD dementia. In this webinar, our speakers address important trends in the identification of patient populations suitable for trials of cognition-enhancing or disease-modifying therapies.

March 20, 2019
How to Leverage eCOA for Improved Signal Detection in Pediatric & Rare Disorder Trials

How to Leverage eCOA for Improved Signal Detection in Pediatric & Rare Disorder Trials

High-quality data are critical when seeking to measure treatment outcomes, but this is especially true and challenging in rare disease trials. This webinar outlines how clinical trial sponsors are incorporating leading-edge data capture and monitoring strategies to optimize clinical outcome assessments.

March 4, 2019
Selecting CNS Endpoint Measures in Pediatric and Rare Disease Clinical Trials: Key Considerations for Cognitive and Behavioral Assessments

Selecting CNS Endpoint Measures in Pediatric and Rare Disease Clinical Trials: Key Considerations for Cognitive and Behavioral Assessments

Testing new medicines in children and patients with rare diseases presents considerable challenges, not the least of which is proper endpoint selection and measurement. This webinar discusses critical considerations when selecting developmental and computerized assessments for children.

May 21, 2018
The ABCs of Assessing Cognition in Oncology Clinical Trials: Applications, Benefits, and Considerations

The ABCs of Assessing Cognition in Oncology Clinical Trials: Applications, Benefits, and Considerations

Nearly all patients with central nervous system cancers experience cognitive problems during the course of their disease and treatment that can result in diminished quality of life and functional independence. This webinar discusses the role and relevance of cognitive endpoints in clinical trials to accelerate understanding of cognitive dysfunction related to cancer and cancer treatments.

May 17, 2017
Increasing the Precision of Cognitive Endpoints in Schizophrenia Clinical Trials

Increasing the Precision of Cognitive Endpoints in Schizophrenia Clinical Trials

Cognitive impairment associated with schizophrenia (CIAS) is an important treatment target, and major unmet therapeutic need in the chronic stages of schizophrenia. Many studies have sought to ameliorate CIAS with new drugs but, as yet, no drug has been approved for treatment of CIAS. This webinar outlines issues associated with the application of cognitive tests to guide decision making about the safety and efficacy of drugs in schizophrenia.

February 13, 2017

How can we help you optimize the measurement of brain health?

Please fill out the form to get in touch